Loading organizations...

COMPASS Pathways is a technology company.
COMPASS Pathways is a biotechnology company focused on developing evidence-based innovations for mental health conditions. Its primary product, COMP360 psilocybin treatment, is an investigational therapy currently undergoing global Phase 3 trials for individuals living with treatment-resistant depression. The company's technical approach centers on rigorous scientific development and clinical evaluation of novel psychedelic-assisted therapies, with additional pipeline targets including post-traumatic stress disorder and anorexia nervosa.
The company was founded in 2016 by George Goldsmith and Ekaterina Malievskaia, M.D. Their shared insight stemmed from a profound personal experience with mental illness within their family, recognizing a critical unmet need for more effective treatments. This led them to unite experienced entrepreneurs and scientists with a passion for exploring the therapeutic potential of carefully researched psychedelic compounds.
COMPASS Pathways aims to serve patients suffering from severe mental health conditions who have not responded to existing therapies. The company’s vision is to transform mental health care by integrating scientific discovery with compassionate patient care. It seeks to accelerate access to innovative and effective treatments globally, striving to connect science and compassion to fundamentally reimagine mental health care.
COMPASS Pathways has raised $365.1M across 2 funding rounds.
COMPASS Pathways has raised $365.1M in total across 2 funding rounds.
COMPASS Pathways has raised $365.1M in total across 2 funding rounds.
COMPASS Pathways's investors include Aisling Capital, TCGX, Armistice Capital, Laurion Capital Management, Logos Capital, Paradigm BioCapital, PFM Health Sciences, RA Capital Management, Soleus Capital, Surveyor Capital, Vivo Capital, Sean Rad.
Compass Pathways is a biotechnology company, not a technology company in the traditional software or hardware sense, specializing in psychedelic-based mental health treatments. It develops COMP360, an investigational psilocybin therapy delivered with psychological support, primarily targeting treatment-resistant depression (TRD), with ongoing programs in post-traumatic stress disorder (PTSD) and anorexia nervosa.[1][2][3][5] The company serves patients in the mental health sector facing unmet needs where few effective options exist, aiming to accelerate evidence-based innovations through rigorous clinical trials, including the largest psilocybin studies ever conducted across multiple countries.[2][5] Post-IPO in 2020 with $113M raised and a current market cap of $0.43B, it maintains Phase 3 trials for TRD (with FDA breakthrough status) and has faced recent workforce reductions amid regulatory challenges in the psychedelic space.[1][3]
Compass Pathways originated as a nonprofit in 2015 (or 2016 per some records), founded to advance psilocybin therapy for mental health, before transitioning to a for-profit model.[3][6] Key backers included biotech investor Christian Angermayer (Apeiron Investment Group), Peter Thiel, Mike Novogratz's Galaxy Investment Partners, and Sam Englebardt, providing crucial early funding and expertise.[3][6] The idea emerged from growing evidence on psychedelics' potential, spurred by academic research; pivotal early moments included completing preclinical GMP manufacturing, launching the world's first large-scale psilocybin trials for TRD in 2018 via partnerships like Worldwide Clinical Trials, and achieving NASDAQ listing as the first psychedelic firm in 2020.[1][3][6] This evolution shifted focus from exploratory nonprofit work to global Phase 3 programs, humanizing its mission through values like compassion and scientific rigor.[2]
Compass Pathways rides the psychedelic renaissance trend, blending neuroscience, psychopharmacology, and digital tools (e.g., AI platforms) to redefine mental health care amid a crisis affecting millions with inadequate treatments.[2][5] Timing aligns with post-2020 regulatory shifts, FDA breakthrough status, and growing acceptance of psychedelics beyond MDMA setbacks (e.g., Lykos rejection in 2024), positioning it as the largest player in a nascent industry.[3] Market forces like rising TRD prevalence, investor interest from tech moguls, and partnerships with CROs/academia favor scalable GMP production and global trials, influencing the ecosystem by pioneering evidence-based protocols, encouraging publications, and sparking preclinical discoveries that could standardize psychedelic integration into healthcare.[1][3][6]
Compass Pathways' Phase 3 TRD data readout could catalyze approvals, narrowing focus post-2024 layoffs (30% workforce cut) to core pipeline amid FDA scrutiny.[3][5] Trends like AI-enhanced therapy, prodrug advancements, and expanding investigator studies (e.g., MDD signals from Imperial College) will shape progress, potentially evolving its influence from pioneer to market leader if access barriers ease.[2][5] Watch for regulatory wins and partnerships to drive growth, reimagining mental health from limited options to innovative, compassionate care—echoing its founding drive to connect science and suffering's relief.[2]
COMPASS Pathways has raised $365.1M across 2 funding rounds. Most recently, it raised $285.1M Other Equity in August 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 17, 2023 | $285.1M Other Equity | Aisling Capital, TCGX | Armistice Capital, Laurion Capital Management, Logos Capital, Paradigm BioCapital, PFM Health Sciences, RA Capital Management, Soleus Capital, Surveyor Capital, Vivo Capital |
| Apr 1, 2020 | $80.0M Series B | Sean Rad, Able Partners, ATAI Life Sciences, Camden Partners, Peter Thiel, Otsuka, Perceptive Advisors, Skyviews Life Science, Soleus Capital |